# Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer

> **NCT00878709** · PHASE3 · COMPLETED · sponsor: **Puma Biotechnology, Inc.** · enrollment: 2840 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** neratinib
- **OTHER:** placebo

## Key facts

- **NCT ID:** NCT00878709
- **Lead sponsor:** Puma Biotechnology, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-07-09
- **Primary completion:** 2014-08-21
- **Final completion:** 2019-10-04
- **Target enrollment:** 2840 (ACTUAL)
- **Last updated:** 2021-06-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00878709

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00878709, "Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00878709. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*